Tag Archives: ICPT

Intercept Pharma (ICPT) Receives a Buy from B.Riley FBR

In a report released yesterday, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Intercept Pharma (ICPT – Research Report). The company’s shares closed yesterday at $117.34. Mamtani commented: “Sciences, Inc. announced negative results from their Ph. III STELLAR-4

Analysts Offer Insights on Healthcare Companies: Intercept Pharma (NASDAQ: ICPT) and Aerie Pharma (NASDAQ: AERI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intercept Pharma (ICPT – Research Report) and Aerie Pharma (AERI – Research Report) with bullish sentiments. Intercept Pharma (ICPT) Oppenheimer analyst Jay

Intercept Pharma (ICPT) Received its Third Buy in a Row

After Cowen & Co. and Laidlaw gave Intercept Pharma (NASDAQ: ICPT) a Buy rating last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Alethia Young maintained a Buy rating on Intercept Pharma yesterday and set a

Cantor Fitzgerald Reiterates a Buy Rating on Intercept Pharma (ICPT)

Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Intercept Pharma (ICPT – Research Report) today and set a price target of $170. The company’s shares opened today at $104.56. Young observed: “: We reiterate our Overweight rating and

Analyst Explains Why They Upgraded Their Rating on Intercept Pharma (ICPT)

Oppenheimer analyst Jay Olson upgraded Intercept Pharma (ICPT – Research Report) to Buy yesterday and set a price target of $140. The company’s shares closed on Friday at $102.70. Olson said: “We upgrade ICPT to Outperform based on our view

Analysts’ Top Healthcare Picks: Intercept Pharma (ICPT), Adamas Pharmaceuticals (ADMS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intercept Pharma (NASDAQ:ICPT), Adamas Pharmaceuticals (NASDAQ:ADMS) and Adverum Biotechnologies (NASDAQ:ADVM) with bullish sentiments. Intercept Pharma (ICPT) Cowen & Co. analyst Ritu Baral